Bringing doctors together

or

A free, private network for verified physicians

Leading voices

Dr. Hope Rugo

Breast Oncology · City of Hope

View

Dr. Virginia Borges

Breast Oncology · CU Anschutz Medical Campus

View

Dr. William Gradishar

Breast Oncology · NU

View

Dr. Jame Abraham

Breast Oncology · Cleveland Clinic

View

Dr. Azka Ali

Breast Oncology · Cleveland Clinic Lerner

View

Dr. Amy Comander

Breast Oncology · PHS

View

Dr. Paolo Tarantino

Breast Oncology · Dana-Farber Cancer Institute

View

Dr. Anastasia Martynova

Breast Oncology · USC

View

Dr. Rani Bansal

Breast Oncology · Duke

View

Dr. Gilbert Bader

Breast Oncology · OSUMC

View
  • Discover your community

  • Stay current

  • A profile that represents you

  • Find your people

About RoonPrivacyTerms
    MJDr. Mohammad Jahanzeb

    Dr. Mohammad Jahanzeb

    Hematology & Oncology · Breast Oncology
    Florida Atlantic University Charles E. Schmidt College of Medicine
    mohammadj
    Boca Raton, FL, USA

    Research

    A randomized phase III double-blind placebo-controlled trial of first-line chemotherapy and trastuzumab with or without bevacizumab for patients with HER2/neu-positive metastatic breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1105)

    2024

    Via Breast Cancer Research and Treatment

    Research

    International experts consensus on optimal central vascular access device selection and management for patients with cancer

    2024

    Via The Journal of Vascular Access

    Research

    Real-World Efficacy and Tolerability of Brigatinib in Patients with Non-Small Cell Lung Cancer with Prior ALK-TKIs in the United States

    2022

    Via The Oncologist

    Research

    Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry

    2021

    Via Breast Cancer Research and Treatment

    Research

    Health-related quality of life in the randomized phase III trial of brigatinib vs crizotinib in advanced ALK inhibitor-naive ALK+ non-small cell lung cancer (ALTA-1L)

    2021

    Via Lung Cancer

    Research

    Multi-omic molecular profiling guide's efficacious treatment selection in refractory metastatic breast cancer: a prospective phase II clinical trial

    2021

    Via Molecular Oncology

    Research

    Resource-Stratified Guideline-Based Cancer Care Should Be a Priority: Historical Context and Examples of Success

    2020

    Via American Society of Clinical Oncology Educational Book

    Research

    Economic burden in patients with ALK+ non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors

    2020

    Via Journal of Medical Economics

    Research

    International Perspective on the Pursuit of Quality in Cancer Care: Global Application of QOPI and QOPI Certification

    2020

    Via JCO Global Oncology

    Research

    Real-World Treatment Patterns and Progression-Free Survival Associated with Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor Therapies for ALK+ Non-Small Cell Lung Cancer

    2020

    Via The Oncologist

    Research

    Improving Quality of Cancer Care by Participating in Quality Oncology Practice Initiative Certification Program

    2020

    Via JCO Global Oncology

    Research

    Response to Abemaciclib After 10 Lines of Therapy Including Palbociclib in Metastatic Breast Cancer: A Case Report With Literature Review

    2020

    Via Oncology and Therapy

    Research

    Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

    2020

    Via Journal of Thoracic Oncology

    Research

    Remarkable Role of Chemotherapy in Selected ALK-Positive Non-Small-Cell Lung Cancer Before or After Targeted Therapy: Two Case Reports

    2020

    Via JCO Precision Oncology

    Research

    Immunotherapy Treatment Patterns and Outcomes Among ALK-Positive Patients With Non-Small-Cell Lung Cancer

    2020

    Via Clinical Lung Cancer